Cytokine release syndrome: Who is at risk and how to treat
- 1 December 2017
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 30 (4), 336-340
- https://doi.org/10.1016/j.beha.2017.09.002
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Toxicity management for patients receiving novel T-cell engaging therapiesCurrent Opinion in Pediatrics, 2014
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood, 2012
- Engineering lymphocyte subsets: tools, trials and tribulationsNature Reviews Immunology, 2009
- The promise and potential pitfalls of chimeric antigen receptorsCurrent Opinion in Immunology, 2009
- The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructCancer Immunology, Immunotherapy, 2007
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006